| FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
STATUS |
| Interferons -
Mimic naturally-occurring, infection-fighting immune
substance produced in the body |
Intron A
(Interferon
alfa-2b |
Immunomodulator |
Merck,
Whitehouse Station, NJ |
FDA Approved
1991 |
Pegasys
(Peginterferon alfa-2a) |
Immunomodulator |
Genentech,
South SanFrancisco, CA |
FDA Approved 2005 |
| There are other brands of interferon
approved for HCV treatment, but they have not been
FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La
Roche), and Infergen (Amgen) |
| Nucleoside Analogues
- Interfere with the viral DNA polymerase
enzyme used for hepatitis B virus reproduction |
Epivir-HBV
(Lamivudine) |
Inhibits viral DNA polymerase |
GlaxoSmithKline Philadelphia, PA |
FDA Approved
1998 |
Hepsera
(Adefovir Dipivoxil) |
Inhibits viral DNA polymerase |
Gilead
Foster City, CA |
FDA Approved
2002 |
Baraclude
(Entecavir) |
Inhibits viral DNA polymerase |
Bristol-Myers
Squibb
Princeton, NJ |
FDA Approved
2005
|
Tyzeka
Sebivo (Europe)
(Telbivudine) |
Inhibits viral DNA polymerase |
Novartis,
Switzerland |
FDA Approved
2006 |
Viread
(Tenofovir) |
Inhibits viral DNA polymerase |
Gilead
Foster City, CA |
FDA Approved 2008 |
Clevudine
(L-FMAU)
|
Inhibits viral DNA polymerase |
Bukwang
South Korea
Eiasai, Japan |
Approved S. Korea
2006 (Levovir) |
MIV-210
|
Inhibits viral DNA polymerase |
Medivir/Daewoong
South Korea |
Phase II |
Amdoxovir
(DAPD) |
Inhibits viral DNA polymerase |
RFS Pharm LLC
Tucker, GA |
Phase II |
| AGX-1009 |
Prodrug of Tenofovir |
Agenix, Australia |
Phase I, China |
| Non-Nucleoside
Antivirals - Interfere with proteins
involved in viral reproduction |
NOV-205
(BAM 205) |
Small Molecule |
Novelos
Newton, MA |
Approved in Russia |
| LB80380 (ANA380) |
Inhibits viral RNA polymerase |
LG Life Sciences,
S. Korea |
Phase II |
| Myrcludex B |
Entry Inhibition |
Myr-GmbH,
Germany |
Phase IA, Germany |
HAP Compound
Bay 41-4109 |
Inhibits viral nucleocapsid |
AiCuris,
Germany |
Phase I |
| REP 9AC |
HBsAg Release Inhibitor |
REPLICor Inc.
Montreal, Quebec |
Phase I |
| Alinia (Nitazoxanide) |
Small Molecule |
Romark Labs
Tampa, FL |
Preclinical |
| dd-RNAi compound |
Gene silencing |
Benitec, Australia
and Biomics, China |
Preclinical |
| ARC-520 |
RNAi gene silencer |
Arrowhead Research, Pasadena, CA |
Preclinical |
| NVR-1221 |
Capsid inhibitor |
Novira Therapeutics, Doylestown, PA |
Preclinical |
| Non-Interferon
Immune Enhancers - Boost T-cell infection-fighting
immune cells and natural interferon production |
Zadaxin
(Thymosin
alpha-1) |
Immune stimulator |
SciClone
San Mateo, CA |
Orphan drug approval in US for liver cancer |
| CYT107 (Interleukin-7) |
Immunemodulator |
Cytheris,
Paris, France |
Phase I/IIa |
| DV-601 |
HBV surface and core antigens |
Dynavax,
Berkeley, CA |
Phase Ib |
| HBV Core Antigen Vaccine |
Therapeutic HBV vaccine |
Emergent Europe, U.K. |
Phase I |
| GS-9620 |
TLR7 agonist |
Gilead
Foster City, USA |
Phase I |
| GI13000 |
HBV Antigen |
Globe Immune
Louisville, CO |
Preclinical with Gilead |
| Post-Exposure
and/or Post-Liver Transplant Treatment |
| HyperHEP S/D |
HBV Immuneglobulin |
Talecris
RTP, NC |
FDA Approved 1977 |
| Nabi-HB |
HBV Immuneglobulin |
Biotest,
Boca Raton, FL |
FDA Approved
1999 |
| Hepa Gam B |
HBV Immuneglobulin |
Cangene
Canada |
FDA Approved 2006 |
